This transient effect could be explained by the generation of therapeutic antibody-neutralizing antibodies, since the anti-PD-1 mAb used in the study was derived from rat; the overall kinetics of loss of anti-tumor activity is consistent with this mechanism. The gene discussed is PDCD1; the disease is neoplasm.